Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002207 | 0.92 | KCNH2 (0.54) | KCNH2KCNA3DRD2 | |
| SCHEMBL19106955 | 0.88 | KCNH2 (0.51) | KCNH2KCNA3ATMKCNQ1CACNA1C | |
| SCHEMBL19094960 | 0.87 | KCNH2 (0.49) | KCNH2KCNA3ATMKCNQ1CACNA1C | |
| SCHEMBL12002142 | 0.87 | KCNH2 (0.49) | KCNH2KCNA3ATMKCNQ1CACNA1C | |
| SCHEMBL10285563 | 0.87 | KCNH2 (0.58) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL14679203 | 0.86 | KCNH2 (0.56) | KCNH2KCNA3DRD2 | |
| SCHEMBL20511757 | 0.86 | KCNH2 (0.52) | KCNH2KCNA3ATMKCNQ1CACNA1C | |
| SCHEMBL19106960 | 0.86 | KCNH2 (0.50) | KCNH2KCNA3ATMKCNQ1CACNA1C | |
| SCHEMBL19094630 | 0.86 | KCNH2 (0.49) | KCNH2KCNA3ATMDRD2 | |
| SCHEMBL12090600 | 0.85 | KCNH2 (0.54) | KCNH2KCNA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018172925-A1 | INHIBITORS OF DNA GYRASE FOR TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PVT LTD (IN) | 2018-09-27 | — | — | WO | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | KCNH2 4625/4885KCNA3 4657/4885ATM 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.